ZVRA vs KRYS vs RARE vs RCKT

For growth investors, Zevra Therapeutics, Inc.

(ZVRA) is the stronger pick with 350. 9% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Zevra Therapeutics, Inc. (ZVRA) offers the better valuation at 8. 1x trailing P/E (22. 6x forward), making it the more compelling value choice. Analysts rate Zevra Therapeutics, Inc. (ZVRA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zevra Therapeutics, Inc.

(ZVRA) is the cheapest at 8. 1x versus Krystal Biotech, Inc. at 43. 4x. On forward P/E, Zevra Therapeutics, Inc. is actually cheaper at 22. 6x.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +319. 2%, compared to -91. 6% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: KRYS returned +26. 9% versus RCKT's -91. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zevra Therapeutics, Inc.

(ZVRA) is the lower-risk stock at 0. 63β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 123% more volatile than ZVRA relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 41% for Zevra Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zevra Therapeutics, Inc.

(ZVRA) is pulling ahead at 350. 9% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Zevra Therapeutics, Inc. grew EPS 159. 2% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, ZVRA leads at 118. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zevra Therapeutics, Inc.

(ZVRA) is the more profitable company, earning 78. 2% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 78. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zevra Therapeutics, Inc.

(ZVRA) trades at 22. 6x forward P/E versus 39. 3x for Krystal Biotech, Inc. — 16. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZVRA: 120. 5% to $24. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Zevra Therapeutics, Inc.

(ZVRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63)). Both have compounded well over 10 years (ZVRA: -90. 9%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZVRA is a small-cap high-growth stock; KRYS is a small-cap high-growth stock; RARE is a small-cap high-growth stock; RCKT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.